{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:48:12Z","timestamp":1791301692083,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,19]],"date-time":"2016-05-19T00:00:00Z","timestamp":1463616000000},"content-version":"vor","delay-in-days":384,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunity"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.immuni.2015.04.018","type":"journal-article","created":{"date-parts":[[2015,5,28]],"date-time":"2015-05-28T19:23:36Z","timestamp":1432841016000},"page":"826-838","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":177,"title":["Interleukin-2 Activity Can Be Fine Tuned with Engineered Receptor Signaling Clamps"],"prefix":"10.1016","volume":"42","author":[{"given":"Suman","family":"Mitra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron\u00a0M.","family":"Ring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoba","family":"Amarnath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie\u00a0B.","family":"Spangler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jangsuk","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanne","family":"Spolski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kipp","family":"Weiskopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holbrook","family":"Kohrt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason\u00a0E.","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumati","family":"Rajagopalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric\u00a0O.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel\u00a0H.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas\u00a0A.","family":"Waldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.\u00a0Christopher","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren\u00a0J.","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.immuni.2015.04.018_bib1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJM200003023420902","article-title":"Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody","volume":"342","author":"Beniaminovitz","year":"2000","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2015.04.018_bib2","doi-asserted-by":"crossref","first-page":"8705","DOI":"10.1073\/pnas.0402653101","article-title":"Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta","volume":"101","author":"Bielekova","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2015.04.018_bib3","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1182\/blood-2004-05-1687","article-title":"Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease","volume":"105","author":"Blaser","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.immuni.2015.04.018_bib4","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nri3156","article-title":"The role of interleukin-2 during homeostasis and activation of the immune system","volume":"12","author":"Boyman","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.immuni.2015.04.018_bib5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1600-065X.2011.01004.x","article-title":"T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells","volume":"241","author":"Cheng","year":"2011","journal-title":"Immunol. Rev."},{"issue":"2","key":"10.1016\/j.immuni.2015.04.018_bib6","doi-asserted-by":"crossref","first-page":"S324","DOI":"10.1016\/j.jaci.2009.11.014","article-title":"Transplantation immunology: solid organ and bone marrow","volume":"125","author":"Chinen","year":"2010","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.immuni.2015.04.018_bib7","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.4049\/jimmunol.130.5.2203","article-title":"The fate of interleukin-2 after in\u00a0vivo administration","volume":"130","author":"Donohue","year":"1983","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2015.04.018_bib8","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.4049\/jimmunol.137.6.1874","article-title":"Amelioration of acute graft vs host disease due to minor histocompatibility antigens by in\u00a0vivo administration of anti-interleukin 2 receptor antibody","volume":"137","author":"Ferrara","year":"1986","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2015.04.018_bib9","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/S0140-6736(12)62190-4","article-title":"Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial","volume":"381","author":"Gold","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.immuni.2015.04.018_bib10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1083\/jcb.129.1.55","article-title":"Endocytosis of interleukin 2 receptors in human T lymphocytes: distinct intracellular localization and fate of the receptor alpha, beta, and gamma chains","volume":"129","author":"H\u00e9mar","year":"1995","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.immuni.2015.04.018_bib11","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1056\/NEJMoa032953","article-title":"Daclizumab to prevent rejection after cardiac transplantation","volume":"352","author":"Hershberger","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2015.04.018_bib12","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1182\/blood-2010-09-305425","article-title":"CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T\u00a0cells from patients with ATL and HAM\/TSP","volume":"117","author":"Ju","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.immuni.2015.04.018_bib13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.immuni.2009.11.010","article-title":"Prolonged interleukin-2Ralpha expression on virus-specific CD8+ T\u00a0cells favors terminal-effector differentiation in\u00a0vivo","volume":"32","author":"Kalia","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2015.04.018_bib14","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cytogfr.2006.07.003","article-title":"Both integrated and differential regulation of components of the IL-2\/IL-2 receptor system","volume":"17","author":"Kim","year":"2006","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.immuni.2015.04.018_bib15","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.4049\/jimmunol.150.8.3357","article-title":"Unexpected effects of the IL-2 receptor alpha subunit on high affinity IL-2 receptor assembly and function detected with a mutant IL-2 analog","volume":"150","author":"Kuziel","year":"1993","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2015.04.018_bib16","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1186\/gb-2009-10-3-r25","article-title":"Ultrafast and memory-efficient alignment of short DNA sequences to the human genome","volume":"10","author":"Langmead","year":"2009","journal-title":"Genome Biol."},{"key":"10.1016\/j.immuni.2015.04.018_bib17","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.immuni.2007.02.009","article-title":"Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation","volume":"26","author":"Laurence","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2015.04.018_bib18","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/353858a0","article-title":"Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis","volume":"353","author":"Lenardo","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2015.04.018_bib19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10975","article-title":"Exploiting a natural conformational switch to engineer an interleukin-2 \u2018superkine\u2019","volume":"484","author":"Levin","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2015.04.018_bib20","doi-asserted-by":"crossref","first-page":"ra50","DOI":"10.1126\/scisignal.2004998","article-title":"Multifaceted activities of type I interferon are revealed by a receptor antagonist","volume":"7","author":"Levin","year":"2014","journal-title":"Sci. Signal."},{"key":"10.1016\/j.immuni.2015.04.018_bib21","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/ni.1656","article-title":"Priming for T helper type 2 differentiation by interleukin 2-mediated induction of interleukin 4 receptor alpha-chain expression","volume":"9","author":"Liao","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2015.04.018_bib22","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/ni.2030","article-title":"Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T\u00a0cell lineages","volume":"12","author":"Liao","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2015.04.018_bib23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.immuni.2013.01.004","article-title":"Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy","volume":"38","author":"Liao","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2015.04.018_bib24","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.cell.2010.02.021","article-title":"Th17 and regulatory T\u00a0cells in mediating and restraining inflammation","volume":"140","author":"Littman","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2015.04.018_bib25","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1084\/jem.162.6.2169","article-title":"Origin of human T-lymphotrophic virus I-positive T\u00a0cell lines in adult T\u00a0cell leukemia. Analysis of T\u00a0cell receptor gene rearrangement","volume":"162","author":"Maeda","year":"1985","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2015.04.018_bib26","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1126\/science.181845","article-title":"Selective in\u00a0vitro growth of T lymphocytes from normal human bone marrows","volume":"193","author":"Morgan","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.immuni.2015.04.018_bib27","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1073\/pnas.0509575103","article-title":"Preclinical and phase I clinical trial of blockade of IL-15 using Mikbeta1 monoclonal antibody in T\u00a0cell large granular lymphocyte leukemia","volume":"103","author":"Morris","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2015.04.018_bib28","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/369330a0","article-title":"Heterodimerization of the IL-2 receptor beta- and gamma-chain cytoplasmic domains is required for signalling","volume":"369","author":"Nakamura","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2015.04.018_bib29","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/369333a0","article-title":"Cytoplasmic domains of the interleukin-2 receptor beta and gamma chains mediate the signal for T-cell proliferation","volume":"369","author":"Nelson","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2015.04.018_bib30","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0092-8674(93)90167-O","article-title":"Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans","volume":"73","author":"Noguchi","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2015.04.018_bib31","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.immuni.2009.11.012","article-title":"Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T\u00a0cells","volume":"32","author":"Pipkin","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2015.04.018_bib32","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.pep.2005.09.027","article-title":"Single step protocol to purify recombinant proteins with low endotoxin contents","volume":"46","author":"Reichelt","year":"2006","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.immuni.2015.04.018_bib33","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1126\/science.1109745","article-title":"The structure of interleukin-2 complexed with its alpha receptor","volume":"308","author":"Rickert","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.immuni.2015.04.018_bib34","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1517\/17460441.2011.547468","article-title":"Ligand-based receptor tyrosine kinase partial agonists: New paradigm for cancer drug discovery?","volume":"6","author":"Riese","year":"2011","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.immuni.2015.04.018_bib35","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ni.2449","article-title":"Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15","volume":"13","author":"Ring","year":"2012","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2015.04.018_bib36","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nri2580","article-title":"New insights into the regulation of T\u00a0cells by gamma(c) family cytokines","volume":"9","author":"Rochman","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.immuni.2015.04.018_bib37","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2015.04.018_bib38","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1084\/jem.161.5.1169","article-title":"Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2","volume":"161","author":"Rosenberg","year":"1985","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.immuni.2015.04.018_bib39","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1038\/sj.bjp.0707672","article-title":"Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors","volume":"153","author":"Strange","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.immuni.2015.04.018_bib40","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.copbio.2009.10.011","article-title":"Optimization of Fc-mediated effector functions of monoclonal antibodies","volume":"20","author":"Strohl","year":"2009","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.immuni.2015.04.018_bib41","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.immuni.2008.03.016","article-title":"Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction","volume":"28","author":"Tang","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2015.04.018_bib42","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.4049\/jimmunol.1301159","article-title":"Cutting edge: NK cell licensing modulates adhesion to target cells","volume":"191","author":"Thomas","year":"2013","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2015.04.018_bib43","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1126\/science.1144603","article-title":"Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange","volume":"317","author":"van der Neut Kolfschoten","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.immuni.2015.04.018_bib44","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJM199801153380304","article-title":"Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation","volume":"338","author":"Vincenti","year":"1998","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.immuni.2015.04.018_bib45","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nri1901","article-title":"The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design","volume":"6","author":"Waldmann","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.immuni.2015.04.018_bib46","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1182\/blood-2012-08-450585","article-title":"Phase 1 trial of IL-15 trans presentation blockade using humanized Mik\u03b21 mAb in patients with T-cell large granular lymphocytic leukemia","volume":"121","author":"Waldmann","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.immuni.2015.04.018_bib47","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1126\/science.1117893","article-title":"Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors","volume":"310","author":"Wang","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.immuni.2015.04.018_bib48","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.4049\/jimmunol.134.3.1623","article-title":"TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells)","volume":"134","author":"Yodoi","year":"1985","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.immuni.2015.04.018_bib49","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.immuni.2008.11.014","article-title":"A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells","volume":"30","author":"Yu","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2015.04.018_bib50","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev-immunol-030409-101212","article-title":"Differentiation of effector CD4 T\u00a0cell populations (\u2217)","volume":"28","author":"Zhu","year":"2010","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.immuni.2015.04.018_bib51","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1002\/j.1460-2075.1993.tb06206.x","article-title":"Definition and spatial location of mouse interleukin-2 residues that interact with its heterotrimeric receptor","volume":"12","author":"Zurawski","year":"1993","journal-title":"EMBO J."}],"container-title":["Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074761315001788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074761315001788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T19:29:15Z","timestamp":1691695755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1074761315001788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S1074761315001788"],"URL":"https:\/\/doi.org\/10.1016\/j.immuni.2015.04.018","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725506811.793547224","asserted-by":"object"}]},"ISSN":["1074-7613"],"issn-type":[{"value":"1074-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-2 Activity Can Be Fine Tuned with Engineered Receptor Signaling Clamps","name":"articletitle","label":"Article Title"},{"value":"Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.immuni.2015.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.immuni.2015.04.015","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}